



## **TRIREME MEDICAL FACILITY IN SINGAPORE TO FOCUS ON NEW THERAPEUTIC DEVICES**

- *Singapore team developed the Chocolate™ PTA Balloon Catheter, making it the first Singaporean interventional device to receive FDA Approval***

**SINGAPORE, 6 MARCH 2012** — TriReme Medical Inc. (TriReme), a US medical device company dedicated to the development and manufacturing of innovative devices for the treatment of complex vascular disease, announced the official opening of its research & development, global sales and manufacturing centre in Singapore today. Dr Beh Swan Gin, Managing Director of the Singapore Economic Development Board (EDB), was the Guest-of-Honour.

Singapore is the first business unit to be established outside the U.S reflecting management focus on the rapidly growing Asian markets. Headquartered in Pleasanton, California, TriReme was founded in 2005 and its primary focus is to provide innovative tools to improve the success rates in challenging peripheral and coronary interventions.

Dr Eitan Konstantino, founder and CEO of TriReme, said: “We share the government’s vision of making Singapore an international hub for medical technologies. Singapore’s business friendly environment, strategic location, highly educated talent pool and an excellent infrastructure will help Singapore become the “Silicon Valley of the East.”

Located at the International Business Park, the Singapore facility will focus on coronary and peripheral products and will also produce the Chocolate™ PTA Balloon Catheter (Chocolate), the first Singaporean interventional device approved by the US Food and Drug Administration (FDA). This device was developed in Singapore in collaboration with TriReme subsidiary Quattro Vascular and is currently sold in the US and Europe.

“We are indeed proud to receive the FDA approval for Chocolate at a record time of less than two years. Chocolate, which is a catheter used in the treatment of blocked leg arteries, was first conceived in the summer of 2010, funded by TriReme US and Luminor Capital Pte Ltd, a Singapore-based private equity fund, and received the FDA approval in December 2011. The device has been launched in the US and Germany. We are also looking to launch the product in Singapore, China and Japan,” added Dr Konstantino.

Dr. Beh Swan Gin, Managing Director of EDB said, “I am heartened that TriReme has chosen Singapore to carry out its manufacturing, regional headquarter and product development activities. TriReme’s successful commercialisation of Chocolate highlights the speed with which Singapore-based companies can develop a novel device as well as the ease with which it can tap into or create commercial networks to launch new products into the marketplace. It is testimonial of Singapore’s ability to be a key node for innovation and commercialisation in Asia.”

Ms Chu Swee Yeok, CEO of EDBI said “TriReme has proven to be an emerging leader in its field and we are confident that they will continue to create high market potential,

innovative products. We look forward to working closely with TriReme, providing them with the network and support to capitalise on Asia's growth, and build a global leader in cardiovascular devices.”

In addition to Chocolate, the Singapore facility will also produce the Glider™ PTCA Balloon Catheter which is a unique balloon catheter designed to cross through tight lesions even where other balloons are challenged, the GliderfleX® PTA Balloon Catheter which is designed to support a broad range of challenging angioplasty needs, and will support the development and manufacturing of TriReme's Drug Eluting Balloons product line.

TriReme's products include minimally invasive coronary and peripheral devices which offer physicians new and differentiated tools to improve outcomes in complex peripheral and coronary interventions. Its products are distributed worldwide, including the US, Japan, Austria, the Netherlands, France, Germany, Italy, Sweden and Israel.

# # #

**About TriReme Medical, Inc.**

Based in Pleasanton, California, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialisation of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The Company's novel interventional therapies are specifically designed for large, unmet clinical needs. For more information, please visit: <http://www.trirememedical.com>

**About EDBI**

EDBI (EDB Investments) is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences, Clean Technologies, Internet & Digital Media, as well as other strategic industry clusters with commercial potential. As a value adding investor, EDBI creates sustainable and synergistic partnerships with its portfolio companies, leveraging on its broad network of resources and experience to facilitate the companies' organic growth in Asia and the world, through their operations in Singapore. For more information on EDBI, please visit <http://www.edbi.com>.

# # #

**For more information, please contact:-**

Ms Leow Fang Yi / Mr Gan Ling Kai  
Mileage Communications Pte Ltd  
Tel: +65 6222 1678  
Email: [fangyi@mileage.com.sg](mailto:fangyi@mileage.com.sg) / [ganlk@mileage.com.sg](mailto:ganlk@mileage.com.sg)